3B Pharmaceuticals GmbH (3BP) is a German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need. As a leader in peptide discovery and optimization, 3BP has built a technology platform extending from hit identification to early clinical development. Technologies are applied to both in-house and collaborative R&D.
The Company established a recurring revenue base via research and development collaborations with pharmaceutical partners and the out-licensing of pharmaceutical development candidates and affinity purification solutions for protein DSP.
3BP's discovery technology platform has been validated by a long-term, multi-target research collaboration with Baxter Corporation to develop new treatment options in hemophilia.
History. 3BP was founded in 2008 by a team of renowned experts in peptide drug discovery and nuclear medicine from Berlin, Berne and Basel. Following a buyout of Jerini AG's R&D assets the company became operative in 2009 and is based in Berlin Adlershof, a well-established science park in the southeast of Berlin.